Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

Rock Springs Capital

Sabby Capital

Redmile Group

Venrock

Adage Capital Management

Deerfield

Adverum Biotechnologies

Today, we announced the appointment of Dr. C. David Nicholson to Adverum's Board of Directors, bringing extensive expertise as we advance our gene therapy mission. Learn more here: https://bit.ly/3Qtn6y9
#Gtx #AAV7m8

Today, we announced 3-year efficacy and safety results from the OPTIC extension study in patients with wet AMD during the Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California. Learn more here: https://bit.ly/3FJGkL1
#AAO2023 #Gtx #AAV7m8

Today, we announced positive aflibercept protein level data from our ongoing LUNA Phase 2 trial evaluating Ixo-vec for the treatment of wet AMD. Read here for more details: https://bit.ly/3ZvCmi6

Adverum is pleased to welcome Andy Ramelmeier, Ph.D., as our Chief Technology Officer. Dr. Ramelmeier brings more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapies. #gtx7m8

Today, we announced full enrollment in LUNA, our Phase 2 clinical trial evaluating Ixo-vec for the treatment of wet age-related macular degeneration, and reported financial results for the second quarter. Read here for more details: https://bit.ly/45qDcib

Celebrating Juneteenth: Honoring freedom, equality, and the resilience of Black communities. As a company holiday, we encourage our employees to use today to amplify voices, educate, and make a difference. Together, let's commemorate this historic day and work towards a more inclusive future. #Juneteenth

Today, we announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York. The on-demand webcast fireside may be accessed for 90 days here: https://bit.ly/3C5hzaz #JefferiesHealthcare

We are excited to share more about our data being presented at the American Society of Gene & Cell Therapy 2023 Annual Meeting, including data that supports the two doses being evaluated in our LUNA trial and a new program for Geographic Atrophy. Read more about our poster and oral presentations on the Publications page of the Adverum website: https://lnkd.in/gHFrbeHj #aav7m8 #gtx7m8

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	90582e68
crunchbase profile	general
li profile	general	Feb 2, 2024 12:24 AM	34f93722
translate crunchbase fundingrounds	general
peers	general	Feb 2, 2024 12:24 AM	0e3b5ec1
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ADVERUM

Adverum Biotechnologies

Last Close

5.75

22/11 21:00

Market Cap

161.49M

Beta: -

Volume Today

440.65K

Avg: -